Lumos Pharma, Inc. (LUMO)
| Previous close | 7.52 |
| Open | 7.54 |
| Bid | 7.35 x 1000 |
| Ask | 7.50 x 1100 |
| Day's range | 7.41 - 7.64 |
| 52-week range | 7.23 - 36.72 |
| Volume | |
| Avg. volume | 18,408 |
| Market cap | 62.513M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investor conferences: Event: Stifel 2021 Virtual Healthcare Conference – November 16th - 17th Presentation: Presentation November 16th from 3:20-3:50 PM EST 1x1 Meetings: Virtual one-on-one meetings with management November 16th throughout the day Webcast link:
- GlobeNewswire
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sitesSix-month primary outcome data readout from OraGrowtH210 expected 2H 2023 AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the third quarter ending September 30, 2021 and provided an update on clinical programs. “During o
- GlobeNewswire
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2021 financial results after market close on Wednesday, November 3, 2021. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer se
